Resverlogix (RVXC.F) Stock Overview

A late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. More details

RVXC.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Earnings have grown 27.2% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

Negative shareholders equity

Shareholders have been diluted in the past year

+ 2 more risks

RVXC.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW501,009 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

501,009 investors already sharing narratives

View all narratives

Resverlogix Corp. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Resverlogix
Historical stock prices
Current Share Price	CA$0.068
52 Week High	CA$0.21
52 Week Low	CA$0.03
Beta	1.05
1 Month Change	1.49%
3 Month Change	-12.48%
1 Year Change	87.95%
3 Year Change	-14.68%
5 Year Change	-89.20%
Change since IPO	-96.25%

Recent updates

Shareholder Returns

	RVXC.F	US Biotechs	US Market
7D	1.0%	2.3%	0.8%
1Y	87.9%	42.3%	20.2%

Return vs Industry: RVXC.F exceeded the US Biotechs industry which returned 42.3% over the past year.

Return vs Market: RVXC.F exceeded the US Market which returned 20.2% over the past year.

Price Volatility

Is RVXC.F's price volatile compared to industry and market?
RVXC.F volatility
RVXC.F Average Weekly Movement	11.9%
Biotechs Industry Average Movement	10.3%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.2%

Stable Share Price: RVXC.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: RVXC.F's weekly volatility has decreased from 27% to 12% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Don McCaffrey	www.resverlogix.com

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd.

Resverlogix Corp. Fundamentals Summary

How do Resverlogix's earnings and revenue compare to its market cap?
RVXC.F fundamental statistics
Market cap	US$21.80m
Earnings (TTM)	-US$6.22m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.9x

P/E Ratio

Is RVXC.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RVXC.F income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$6.22m
Earnings	-US$6.22m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.018
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-97.8%

How did RVXC.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/07 23:17
End of Day Share Price	2026/07/07 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Resverlogix Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Claude Camiré	Paradigm Capital, Inc.
null null	Roth Capital Partners

Resverlogix Corp.OTCPK:RVXC.F Stock Report